Evidence map›Paper›PMID 21378024›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2011

Depletion of tissue plasminogen activator attenuates lung ischemia-reperfusion injury via inhibition of neutrophil extravasation.

Yunge Zhao, Ashish K Sharma, Damien J LaPar, Irving L Kron, Gorav Ailawadi, Yuan Liu, David R Jones, Victor E Laubach, Christine L Lau

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04606069 (Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult Patients), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04606069 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation

Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult Patients

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2021 to 2023Enrolled5ConditionsCOVID-19, Lung InflammationArmsRegadenoson, Placebo Control
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Mitsugumin 53 mitigation of ischemia-reperfusion injury in a mouse model.The Journal of thoracic and cardiovascular surgery · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Adenosine A1 receptor activation attenuates lung ischemia-reperfusion injury.The Journal of thoracic and cardiovascular surgery · 2013
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yunge ZhaoDivision of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia Health System, Charlottesville, Virginia, USA.
Ashish K Sharma
Damien J LaPar
Irving L Kron
Gorav Ailawadi
Yuan Liu
David R Jones
Victor E Laubach
Christine L Lau
University of Virginia Health System · US

Funding

Cardiovascular Surgery Training ProgramT32HL007849 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KRON, IRVING L., LAUBACH, VICTOR E · 1998 to 2025
$7.0M
Epigenetic and post-translational regulation of the metastasis suppressor BRMS1R01CA136705 · NCI · UNIVERSITY OF VIRGINIA · PI JONES, DAVID R · 2009 to 2013
$1.5M
Adenosine 2A Receptor Signaling in Lung Transplant Injury and RejectionK08HL094704 · NHLBI · UNIVERSITY OF VIRGINIA · PI LAU, CHRISTINE L · 2009 to 2013
$644k
NCI NIH HHS R01 CA136705NHLBI NIH HHS 1K08HL094704-01NHLBI NIH HHS K08 HL094704NHLBI NIH HHS T32 HL007849NHLBI NIH HHS T32HL007849
6 · The paper itself

Abstract

Ischemia-reperfusion (IR) injury following lung transplantation remains a major source of early morbidity and mortality. Histologically, this inflammatory process is characterized by neutrophil infiltration and activation. We previously reported that lung IR injury was significantly attenuated in plasminogen activator inhibitor-1-deficient mice. In this study, we explored the potential role of tissue plasminogen activator (tPA) in a mouse lung IR injury model. As a result, tPA knockout (KO) mice were significantly protected from lung IR injury through several mechanisms. At the cellular level, tPA KO specifically blocked neutrophil extravasation into the interstitium, and abundant homotypic neutrophil aggregation (HNA) was detected in the lung microvasculature of tPA KO mice after IR. At the molecular level, inhibition of neutrophil extravasation was associated with reduced expression of platelet endothelial cell adhesion molecule-1 mediated through the tPA/ LDL receptor-related protein/NF-κB signaling pathway, whereas increased P-selectin triggered HNA. At the functional level, tPA KO mice incurred significantly decreased vascular permeability and improved lung function following IR. Protection from lung IR injury in tPA KO mice occurs through a fibrinolysis-independent mechanism. These results suggest that tPA could serve as an important therapeutic target for the prevention and treatment of acute IR injury after lung transplantation.

Indexed as

Airway ResistanceAnimalsBlood PressureCapillary PermeabilityLung ComplianceMatrix Metalloproteinase 2Matrix Metalloproteinase 9MiceMice, Inbred C57BLMice, KnockoutNeutrophil InfiltrationPeroxidasePlatelet Endothelial Cell Adhesion Molecule-1P-SelectinReperfusion InjuryTissue Plasminogen ActivatorMatrix Metalloproteinase 2Matrix Metalloproteinase 9PeroxidasePlatelet Endothelial Cell Adhesion Molecule-1P-SelectinTissue Plasminogen Activator

Identifiers

PMID21378024
PMCPMC3094027
OpenAlexW2151487550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.